Company intelligence / Profile preview

MSN Laboratories

Hyderabad, Telangana, Indiamsnlabs.com ↗

Ownership: Private
Employees: ~14000
Development stage: Commercial

Overview

MSN Laboratories has a robust commercial portfolio with over 450 APIs and more than 300 finished dosage formulations across major therapeutic areas. The company claims world leadership in active US DMF filings and has launched numerous first-to-file ANDAs and generics globally. It serves over forty million patients in more than sixty-five countries[2].

Therapeutic areas: NephrologyMen's HealthOncologyEndocrinologyOtherGastroenterologyCardiovascularNeurology
Modalities: Small moleculesgeneric drugscomplex formulationsAPIs
Industry: Biotech

Drug pipeline

2 assets

cabozantinib

Development

Indications: Cancer

1 more asset in the full pipeline.

Request access →

Partnerships

Zydus Lifesciences Ltd.

Beyond the preview

Go deeper on MSN Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSN Laboratories.

Explore the full profile